These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20732960)

  • 1. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
    Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
    Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
    Peréz-Soler R; Saltz L
    J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
    Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
    Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
    Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
    Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors.
    Eaby B; Culkin A; Lacouture ME
    Clin J Oncol Nurs; 2008 Apr; 12(2):283-90. PubMed ID: 18390464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
    Jatoi A; Nguyen PL
    Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
    Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
    Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cutaneous side effects of EGFR inhibitors--appearance and management].
    Wollenberg A; Kroth J; Hauschild A; Dirschka T
    Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    Pérez-Soler R
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
    Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
    Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies.
    Segaert S; Tabernero J; Chosidow O; Dirschka T; Elsner J; Mancini L; Maughan T; Morere JF; Santoro A; Sobrero A; Van Cutsem E; Layton A
    J Dtsch Dermatol Ges; 2005 Aug; 3(8):599-606. PubMed ID: 16033478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
    Jia Y; Lacouture ME; Su X; Wu S
    J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.